急性精神病住院病人使用长效注射抗精神病药物和90天再住院率:一项观察性前瞻性研究的结果

IF 4 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Therapeutic Advances in Psychopharmacology Pub Date : 2025-09-09 eCollection Date: 2025-01-01 DOI:10.1177/20451253251367591
Claudio Brasso, Anna Maria Beoni, Gianluca Colli, Giulia Nicoletta Mariani, Paola Rocca
{"title":"急性精神病住院病人使用长效注射抗精神病药物和90天再住院率:一项观察性前瞻性研究的结果","authors":"Claudio Brasso, Anna Maria Beoni, Gianluca Colli, Giulia Nicoletta Mariani, Paola Rocca","doi":"10.1177/20451253251367591","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Poor adherence to antipsychotic medications is the leading cause of relapses and hospitalizations in patients with schizophrenia, resulting in worse functional outcomes and quality of life. Long-acting injectable (LAI) antipsychotics are an effective therapeutic option to improve adherence, but they are often underutilized, particularly during inpatient care.</p><p><strong>Objective: </strong>To investigate the predictive factors for LAI utilization among inpatients with schizophrenia and to assess whether initiating a LAI antipsychotic treatment during hospitalization reduces the risk of readmission.</p><p><strong>Design: </strong>Observational prospective study.</p><p><strong>Methods: </strong>Patients were evaluated at admission, discharge, and after 3 months. Two comparisons were performed: patients who initiated a LAI during the hospitalization versus those who continued with oral antipsychotics, and readmitted versus not-readmitted patients within 3 months. Factors statistically associated with LAI initiation or readmission were entered as independent variables in two backward logistic regression models, having \"LAI initiation\" and \"rehospitalization at three months\" as outcomes.</p><p><strong>Results: </strong>One hundred two patients were included. Twelve were lost at follow-up. Forty-two (44%) initiated an LAI during the admission. Subjects who received LAI were significantly younger, more educated, and less adherent to treatment. Thirty (33%) patients were readmitted within 3 months after discharge. Re-hospitalized subjects had more psychiatric hospitalizations in the past and a lower rate of LAI antipsychotic treatment initiation during the studied hospitalization: 5/39 (13%) patients prescribed a LAI antipsychotic were readmitted within 3 months, compared with 25/51 (49%) prescribed an oral antipsychotic medication (OR = 0.19; <i>p</i> = 0.002).</p><p><strong>Conclusion: </strong>Introducing LAI antipsychotic treatment during a psychiatric hospitalization may reduce the risk of early readmissions, thus facilitating the improvement of the course of the illness and the patient's quality of life.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251367591"},"PeriodicalIF":4.0000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12420969/pdf/","citationCount":"0","resultStr":"{\"title\":\"Use of long-acting injectable antipsychotics in an acute inpatient psychiatric unit and 90-day re-hospitalization rates: results of an observational prospective study.\",\"authors\":\"Claudio Brasso, Anna Maria Beoni, Gianluca Colli, Giulia Nicoletta Mariani, Paola Rocca\",\"doi\":\"10.1177/20451253251367591\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Poor adherence to antipsychotic medications is the leading cause of relapses and hospitalizations in patients with schizophrenia, resulting in worse functional outcomes and quality of life. Long-acting injectable (LAI) antipsychotics are an effective therapeutic option to improve adherence, but they are often underutilized, particularly during inpatient care.</p><p><strong>Objective: </strong>To investigate the predictive factors for LAI utilization among inpatients with schizophrenia and to assess whether initiating a LAI antipsychotic treatment during hospitalization reduces the risk of readmission.</p><p><strong>Design: </strong>Observational prospective study.</p><p><strong>Methods: </strong>Patients were evaluated at admission, discharge, and after 3 months. Two comparisons were performed: patients who initiated a LAI during the hospitalization versus those who continued with oral antipsychotics, and readmitted versus not-readmitted patients within 3 months. Factors statistically associated with LAI initiation or readmission were entered as independent variables in two backward logistic regression models, having \\\"LAI initiation\\\" and \\\"rehospitalization at three months\\\" as outcomes.</p><p><strong>Results: </strong>One hundred two patients were included. Twelve were lost at follow-up. Forty-two (44%) initiated an LAI during the admission. Subjects who received LAI were significantly younger, more educated, and less adherent to treatment. Thirty (33%) patients were readmitted within 3 months after discharge. Re-hospitalized subjects had more psychiatric hospitalizations in the past and a lower rate of LAI antipsychotic treatment initiation during the studied hospitalization: 5/39 (13%) patients prescribed a LAI antipsychotic were readmitted within 3 months, compared with 25/51 (49%) prescribed an oral antipsychotic medication (OR = 0.19; <i>p</i> = 0.002).</p><p><strong>Conclusion: </strong>Introducing LAI antipsychotic treatment during a psychiatric hospitalization may reduce the risk of early readmissions, thus facilitating the improvement of the course of the illness and the patient's quality of life.</p>\",\"PeriodicalId\":23127,\"journal\":{\"name\":\"Therapeutic Advances in Psychopharmacology\",\"volume\":\"15 \",\"pages\":\"20451253251367591\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2025-09-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12420969/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Psychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/20451253251367591\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20451253251367591","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:抗精神病药物依从性差是精神分裂症患者复发和住院的主要原因,导致更差的功能结局和生活质量。长效注射(LAI)抗精神病药物是一种有效的治疗选择,以提高依从性,但他们往往没有充分利用,特别是在住院治疗期间。目的:探讨精神分裂症住院患者LAI使用的预测因素,并评估住院期间开始LAI抗精神病治疗是否能降低再入院风险。设计:观察性前瞻性研究。方法:对患者在入院、出院和3个月后进行评估。进行了两项比较:住院期间开始进行LAI的患者与继续服用口服抗精神病药物的患者,以及3个月内再次入院的患者与未再次入院的患者。在两个反向logistic回归模型中,以“LAI开始”和“3个月后再住院”作为结果,将与LAI开始或再入院统计相关的因素作为自变量输入。结果:纳入102例患者。随访时丢失12例。42人(44%)在入院期间进行了LAI。接受LAI的受试者明显更年轻,受教育程度更高,对治疗的依从性更低。30例(33%)患者出院后3个月内再次入院。再次住院的受试者过去有更多的精神科住院,并且在研究住院期间开始进行LAI抗精神病药物治疗的比率较低:5/39(13%)服用LAI抗精神病药物的患者在3个月内再次入院,而25/51(49%)服用口服抗精神病药物(OR = 0.19; p = 0.002)。结论:在精神科住院期间引入LAI抗精神病药物治疗可降低早期再入院的风险,从而促进病程的改善和患者生活质量的提高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Use of long-acting injectable antipsychotics in an acute inpatient psychiatric unit and 90-day re-hospitalization rates: results of an observational prospective study.

Use of long-acting injectable antipsychotics in an acute inpatient psychiatric unit and 90-day re-hospitalization rates: results of an observational prospective study.

Use of long-acting injectable antipsychotics in an acute inpatient psychiatric unit and 90-day re-hospitalization rates: results of an observational prospective study.

Use of long-acting injectable antipsychotics in an acute inpatient psychiatric unit and 90-day re-hospitalization rates: results of an observational prospective study.

Background: Poor adherence to antipsychotic medications is the leading cause of relapses and hospitalizations in patients with schizophrenia, resulting in worse functional outcomes and quality of life. Long-acting injectable (LAI) antipsychotics are an effective therapeutic option to improve adherence, but they are often underutilized, particularly during inpatient care.

Objective: To investigate the predictive factors for LAI utilization among inpatients with schizophrenia and to assess whether initiating a LAI antipsychotic treatment during hospitalization reduces the risk of readmission.

Design: Observational prospective study.

Methods: Patients were evaluated at admission, discharge, and after 3 months. Two comparisons were performed: patients who initiated a LAI during the hospitalization versus those who continued with oral antipsychotics, and readmitted versus not-readmitted patients within 3 months. Factors statistically associated with LAI initiation or readmission were entered as independent variables in two backward logistic regression models, having "LAI initiation" and "rehospitalization at three months" as outcomes.

Results: One hundred two patients were included. Twelve were lost at follow-up. Forty-two (44%) initiated an LAI during the admission. Subjects who received LAI were significantly younger, more educated, and less adherent to treatment. Thirty (33%) patients were readmitted within 3 months after discharge. Re-hospitalized subjects had more psychiatric hospitalizations in the past and a lower rate of LAI antipsychotic treatment initiation during the studied hospitalization: 5/39 (13%) patients prescribed a LAI antipsychotic were readmitted within 3 months, compared with 25/51 (49%) prescribed an oral antipsychotic medication (OR = 0.19; p = 0.002).

Conclusion: Introducing LAI antipsychotic treatment during a psychiatric hospitalization may reduce the risk of early readmissions, thus facilitating the improvement of the course of the illness and the patient's quality of life.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.90
自引率
2.40%
发文量
35
审稿时长
10 weeks
期刊介绍: Therapeutic Advances in Psychopharmacology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of psychopharmacology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in psychopharmacology, providing a forum in print and online for publishing the highest quality articles in this area.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信